23 Jul, 2026
According to Straits Research, the global inflammatory bowel disease (IBD) treatment market size was valued at $22.26 billion in 2025 and is projected to grow from $23.07 billion in 2026 to $31.13 billion by 2034, at a CAGR of 3.82% during the forecast period 2026–2034.
The term "inflammatory bowel disease" (IBD) refers to conditions characterized by persistent (chronic) inflammation of the digestive tract's tissues. IBD can manifest in numerous ways, including inflammatory colitis. This disorder affects the lining of the large intestine (colon) and rectum, causing inflammation and lesions (ulcers). The goal of treatment for inflammatory bowel disease is to reduce the inflammation that causes its signs and symptoms. In the best-case scenario, this may reduce the risk of complications, long-term remission, and symptom relief.
In most cases, IBD is treated with surgery or medication. Globally rising rates of ulcerative colitis and Crohn's disease are anticipated to drive market expansion over the next few years. The presence of potent pipeline candidates, such as AbbVie's Skyrise (Risankizumab) and Rinvoq (upadacitinib), Lilly's lebrikizumab, and Takeda's subcutaneous formulation of Entyvio (vedolizumab), are likely to contribute to the growth of the market. The government has increased efforts to improve their healthcare as these individuals are more susceptible to contracting infections due to immunosuppressive medications.
A robust product pipeline of over 616 clinical trials for developing alternative therapy options for IBD is anticipated to drive market growth. There is no cure for inflammatory bowel disease (IBD); however, current treatment focuses on reducing inflammation, minimizing the risk of complications, and attaining long-term remission. To ensure patient health, hospitals and other healthcare institutions conduct clinical trials in close collaboration with pharmaceutical companies.
Inflammatory bowel disease (IBD) is treated with antibiotics, immunosuppressants, biologics, and anti-inflammatory drugs. Scientists are currently developing several targeted drugs to treat inflammatory bowel disease (IBD). Inhibitors of Janus kinase three, selective S1P receptor modulators, human interleukin, and DHODH inhibitors are included in these products.
Because biosimilars such as Hormoz, Reflexes, Imraldi, and Inflector offer numerous advantages over more traditional treatment options, the use of effective medications is expected to increase. This is because more people are becoming aware of the benefits of biosimilars. Shortly, additional biosimilars will be available for purchase, including Avsola (manufactured by Amgen Inc.), Cyltezo (manufactured by Boehringer Ingelheim), IXIFI (manufactured by Pfizer Inc.), and Hulio (manufactured by Mylan N.V.).
It is anticipated that demand will increase following the introduction of biosimilars. This is because economies in emergent markets are sensitive to price changes. Increasing biosimilar acceptability for pediatric Crohn's disease will also increase the size of the global market. This will be an essential element. The expansion of emerging markets and investments in developing cutting-edge technologies are additional significant factors propelling the market's growth. These factors could expand the market for conditions that cause colon inflammation.
The North America inflammatory bowel disease treatment market, which captured 49.85% of global revenue in 2025, is propelled by early adoption of advanced biologics, with rapid uptake of Skyrizi supported by strong FDA approvals and specialist gastroenterology networks. High prevalence of insurance-covered infusion centers and value-based reimbursement models accelerates biologic penetration. Extensive use of real-world evidence platforms and integrated EMR systems enables faster therapy optimization and switching, improving long-term treatment outcomes and sustaining regional market dominance.
The Asia Pacific inflammatory bowel disease treatment market is expected to register the fastest growth with a CAGR of 5.57% during the forecast period. This growth is driven by rapid biosimilar adoption, especially anti-TNF biosimilars, which significantly reduce treatment costs and expand biologic access in price-sensitive healthcare systems. Strong regional biologics manufacturing hubs in South Korea, India, and China are improving supply availability and lowering dependency on imports. Increasing participation in multinational IBD clinical trials is enabling earlier access to next-generation therapies, accelerating treatment uptake and strengthening regional therapeutic innovation capacity.
sales@straitsresearch.com